What do systematic reviews say?

Epinephrine vs norepinephrine‐dobutamine

It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine‐dobutamine (very low certainty).

• Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
  RR 1.25 [0.41, 3.77]
  1 study · 30 participants
  Very low

Epinephrine vs norepinephrine‐dobutamine

The review found no eligible studies for this question.

• Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dopexamine vs dopamine

It is very uncertain whether dopexamine changes all‐cause short‐term mortality: time in hospital compared with dopamine (very low certainty).

• Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Very low

Intervention not reported

• Paracetamol (acetaminophen) for prevention or treatment of pain in newborns 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low

Intervention not reported

• Paracetamol (acetaminophen) for prevention or treatment of pain in newborns 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low

Intervention not reported

• Paracetamol (acetaminophen) for prevention or treatment of pain in newborns 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Low

Intervention not reported

• Paracetamol (acetaminophen) for prevention or treatment of pain in newborns 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

Intervention not reported

• Paracetamol (acetaminophen) for prevention or treatment of pain in newborns 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 11 participants
  Very low

Intervention not reported

• Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 289 participants
  Moderate

Intervention not reported

• Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 70 participants
  Low

Intervention not reported

• Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 41 participants
  Low

Intervention not reported

• Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 113 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in ototoxicity An increase in auditory threshold of 20 dB or more over… (low certainty).

• Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
  RR 0.56 [0.04, 7.96]
  3 studies · 266 participants
  Low

Intervention not reported

• Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 245 participants
  Moderate

Alteplase vs urokinase

Alteplase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 0.46 [0.04, 5.24]
  1 study · 99 participants
  Low

Alteplase vs urokinase

Alteplase may leads to higher serious adverse events compared with urokinase (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 5.61 [1.16, 27.11]
  1 study · 99 participants
  Low

Streptokinase vs urokinase

Streptokinase showed no clear difference in mortality compared with urokinase (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 0.32 [0.01, 8.25]
  1 study · 50 participants
  Low

Streptokinase vs urokinase

Streptokinase showed no clear difference in referral for thoracic surgery (open or thorascopic) compared with urokinase (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 1 [0.13, 7.72]
  1 study · 50 participants
  Low

Streptokinase vs urokinase

Streptokinase showed no clear difference in serious adverse events compared with urokinase (low certainty).

• Intra‐pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult… 2019 · Cochrane Headline outcomes only
  OR 5.43 [0.25, 118.96]
  1 study · 50 participants
  Low